Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every contract, funding round, exec hire, and M&A move on Boehringer Ingelheim — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration for Precision Cancer Treatment

Oct 09, 2024•over 1 year ago

Contract Type

partnership

Ingelheim am RheinPharmaceuticalpharmaceuticals

Description

Boehringer Ingelheim and Circle Pharma have announced a new research collaboration and license agreement aimed at developing a first-in-class cyclin inhibitor to halt the growth of cancer cells. The collaboration focuses on targeting proteins involved in cell division regulation, offering hope for those with hard-to-treat cancers.

Company Information

Company

Boehringer Ingelheim

Location

173 Binger Strasse

Ingelheim am Rhein, Rhineland-Palatinate, Germany

About

Boehringer Ingelheim International GmbH is a multinational pharmaceutical company that has transferred the rights of three anti-diabetes trademarks—Gibtulio, Gibtulio Met, and Ajaduo—to Lupin Limited.

Predictive Intelligence
Strategic

ML-powered predictions for Boehringer Ingelheim's next move

Learn about Strategic plan

Related People

Suggested for you

Sign in to view contact details

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months